Summit Therapeutics Inc. (SMMT) — 10-Q Filings

10-Q Filings (6)

• Summit Therapeutics' Losses Skyrocket Amid Soaring R&D Costs — Oct 20, 2025 Risk: high
  Summit Therapeutics Inc. (SMMT) reported a significant increase in net loss and operating expenses for the nine months ended September 30, 2025. The net loss su
• Summit Therapeutics Inc. Q2 2025 10-Q Filing — Aug 11, 2025 Risk: low
  Summit Therapeutics Inc. filed its quarterly report for the period ended June 30, 2025. The company is incorporated in Delaware and its principal executive offi
• Summit Therapeutics Files Q1 2025 10-Q — May 1, 2025 Risk: medium
  Summit Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operations, including chan
• Summit Therapeutics Q3 2024 10-Q Filed — Oct 30, 2024 Risk: medium
  Summit Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company's fiscal year ends on December 31st. The filing includes financial
• 10-Q Filing — Aug 6, 2024
• Summit Therapeutics Files 10-Q for Q1 2024 — May 1, 2024 Risk: low
  Summit Therapeutics Inc. reported its quarterly results for the period ended March 31, 2024. The company's common stock is traded on The Nasdaq Stock Market LLC

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX